The release of cytokines by T cells strongly defines their functional activity in vivo. The ability to produce multiple cytokines has been associated with beneficial immune responses in cancer and infectious diseases, while their progressive loss is associated with T-cell exhaustion, senescence and anergy. Consequently, strategies that enhance the multifunctional status of T cells are a key for immunotherapy. Dendritic cells (DCs) are professional antigen presenting cells that regulate T-cell functions by providing positive and negative co-stimulatory signals. A key negative regulator of T-cell activity is provided by binding of programmed death-1 (PD-1) receptor on activated T cells, to its ligand PD-L1, expressed on DCs. We investigated the impact of interfering with PD-L1/PD-1 co-stimulation on the multifunctionality of T cells, by expression of the soluble extracellular part of PD-1 (sPD-1) or PD-L1 (sPD-L1) in human monocyte-derived DCs during antigen presentation. Expression, secretion and binding of these soluble molecules after mRNA electroporation were demonstrated. Modification of DCs with sPD-1 or sPD-L1 mRNA resulted in increased levels of the co-stimulatory molecule CD80 and a distinct cytokine profile, characterized by the secretion of IL-10 and TNF-a, respectively. Co-expression in DCs of sPD-1 and sPD-L1 with influenza virus nuclear protein 1 (Flu NP1) stimulated Flu NP1 memory T cells, with a significantly higher number of multifunctional T cells and increased cytokine secretion, while it did not induce regulatory T cells. These data provide a rationale for the inclusion of interfering sPD-1 or sPD-L1 in DC-based immunotherapeutic strategies.
INTRODUCTION
Functional and effective T-cell responses are critical for effective immune responses against infectious diseases and cancer. However, in certain circumstances such as chronic viral infections or cancer, effector T cells can be suppressed by various immunosuppressive mechanisms exerted by the compromised cells as well as host immune cells. [1] [2] [3] These T cells lose their ability to proliferate, to produce multiple effector molecules and to lyse target cells. [4] [5] [6] [7] The loss of these multifunctional T-cell responses leads to antigen-specific hyporesponsiveness, and this is a key feature of T-cell exhaustion during chronic viral infections.
In this regard, it is thought that programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) interaction is responsible for the lack of T-cell responsiveness in settings of persistent antigenic stimulation such as those encountered in cancer and chronic infectious diseases. [8] [9] [10] [11] PD-L1 is expressed by most cell types including dendritic cells (DCs), while its receptor PD-1 is only present on certain immune cells, such as activated T cells and regulatory T (Treg) cells. [12] [13] [14] Under physiological conditions, PD-L1/PD-1 binding is critical in the maintenance of peripheral T-cell tolerance, preventing autoimmune responses. 15 Nevertheless, interference of this interaction mainly by systemic administration of blocking antibodies, or targeted silencing, is a promising therapeutic approach to enhance cancer immunotherapy (as PD-L1 is upregulated by cancer cells), [16] [17] [18] [19] [20] 21 Additionally, upregulated PD-1 on monocytes can impair CD4
þ T-cell function by their production of IL-10. 22 In the LCMV mouse model, exhausted CD8 þ T cells also express PD-1, and its blockade enhances anti-viral responses. 23 However, the systemic administration of PD-L1/PD-1 blocking antibodies carries the high risk of breaking peripheral tolerance. It has to be noted that most tissues rely on PD-L1 expression to limit T-cell effector activities that may cause autoimmune attack. To illustrate this, knocking out PD-1 or PD-L1 in mouse models causes severe, lethal autoimmunity, depending on the mouse strain used, partially because CD8 þ T cells do not undergo apoptosis hence the immune response is not terminated. [24] [25] [26] In humans, single-nucleotide polymorphisms of the pdcd1 gene (encoding PD-1) are associated with systemic lupus erythematosus. 27 An attractive alternative to the systemic blockade of the PD-L1/ PD-1 interaction is to target the inhibition of PD-L1/PD-1 co-stimulation during antigen presentation. This local and transient blocking might retain the positive effects needed to effectively boost anti-tumor or -virus immunity, while limiting possible adverse events to a minimum.
In this study, we targeted the inhibition of this negative costimulatory pathway by expressing the soluble extracellular part of PD-1 (sPD-1) or PD-L1 (sPD-L1) transiently in human monocytederived DCs by mRNA electroporation. We demonstrate that this strategy can be exploited to induce multifunctional T cells without induction of Treg cells, as such introducing a strategy that can improve mRNA-based DC vaccines for the treatment of cancer 28 or infectious diseases. 29 
RESULTS

Expression of PD-1 on T cells and of PD-L1 on DCs is increased upon activation
The principal aim of this work was to evaluate the net effect of interfering with the PD-L1/PD-1 interaction during antigen presentation to human T cells by DCs. Therefore, we first evaluated their background expression on these cells. Interestingly, the majority of human monocyte-derived immature DCs expressed PD-L1 (81.0±9.8% with a mean fluorescence intensity of 43.0±6.2) as evaluated by flow cytometry. When DCs were matured by incubation for 2 days with a standard inflammatory cytokine cocktail, PD-L1 expression increased to 97.3 ± 1.2% with a mean fluorescence intensity of 296.0±107.4 (P ¼ 0.023 and P ¼ 0.008, respectively, n ¼ 3) (Figure 1a ). As previously shown, treatment of CD4 þ and CD8 þ T cells with ani-CD3/anti-CD28 coated beads for 5 days significantly increased the expression of PD-1 from 20.0±5.7% to 47.2±2.8% (P ¼ 0.013, n ¼ 3) and from 18.0 ± 5.7% to 48.5 ± 0.7% (P ¼ 0.008, n ¼ 3) after activation of CD4 þ and CD8 þ T cells, respectively ( Figure 1b) .
Characterization of the expression of sPD-1 and sPD-L1 To interfere with the PD-L1/PD-1 interaction at the immunological synapse, we generated mRNA encoding sPD-1 or sPD-L1. The rationale being that during antigen presentation, mRNA-modified DCs would secrete sPD-1 or sPD-L1 during their interaction with T cells. These soluble forms would compete with membrane-bound PD-L1 or PD-1, interfering with its negative stimulation at the immunological synapse. First, we demonstrated the expression of sPD-1 and sPD-L1 in 293T cells, as they are human cells highly susceptible for electroporation. For this purpose, 293T cells were electroporated with mRNA and treated with Brefeldin A followed by intracellular staining and flow cytometry. Both sPD-1 and sPD-L1 were clearly expressed ( Figure 2a, n ¼ 3) .
We also evaluated their secretion to the supernatant by immunoblotting using PD-L1 and PD-1-specific antibodies (Figure 2b, n ¼ 3) . To evaluate the duration of the secretion of the soluble molecules, we designed an ELISA in which sPD-1 or sPD-L1 containing supernatants that were harvested 0-24, 24-48 or 48-72 h after 293T cell modification were evaluated for the presence of sPD-1 or sPD-L1 (Figures 2c and d, n ¼ 3) . Moreover, this system was used to evaluate the stability of the soluble molecules. Therefore, supernatants that were harvested 24 h after 293T cell modification were kept for 3 days at 37 1C, after which the presence of sPD-1 or sPD-L1 was evaluated (Figure 2e, n ¼ 3) . This assay demonstrated that the production of both soluble molecules decreases over time (Figures 2c and d) . Importantly, both soluble molecules were shown to be stable for the evaluated period (Figure 2e ). We additionally demonstrated the ability of the soluble proteins to bind to their respective membrane bound partners. To assess their binding capacities, we used 293T cells expressing membrane bound PD-1 or PD-L1 (Figure 2f ; Supplementary Figure 1 , n ¼ 3).
Immature DCs expressing sPD-1 or sPD-L1 show distinct phenotypic features Immature DCs were electroporated with mRNA encoding sPD-1, sPD-L1 or control mRNA (encoding truncated nerve growth factor receptor (tNGFR)). The following day, we evaluated the expression of classical DC maturation markers including CD40, CD70, CD80, CD83, CD86, PD-L1, PD-L2, HLA I or HLA II by flow cytometry. Interestingly, electroporation of DCs with sPD-1 or sPD-L1 mRNA did not change the surface expression of most markers, apart from CD80, which was significantly increased to 12.4 ± 5.4% and 12.5 ± 5.3% after electroporation with sPD-1 and sPD-L1, respectively (Po0.0268, n ¼ 5) (Figure 3a) . In contrast, CD80 expression remained unchanged when tNGFR was expressed by mRNA electroporation (4.4 ± 2.7%).
We moreover evaluated the secretion of several cytokines including IL-10, IL-12 and TNF-a by these DCs. Interestingly, we observed that DCs electroporated with sPD-1 mRNA secreted higher levels of IL-10 (84.5 ± 22.8 versus 47.5 ± 5.3, Po0.0071, n ¼ 4) (Figure 3b ), whereas DCs electroporated with sPD-L1 mRNA secreted significantly higher levels of TNF-a (328.3±62.1 versus 95.0 ± 5.0, Po0.0003, n ¼ 3) (Figure 3c ) than DCs electroporated with tNGFR mRNA.
Expression of sPD-1 or sPD-L1 by antigen presenting DCs in the immunological synapse dictates the multifunctional character of T cells To evaluate the consequences of sPD-1 and sPD-L1 expression by DCs on the function of T cells during antigen presentation, we first assessed the effects on the proliferative capacity of CD4 þ and CD8 þ T cells. For this purpose, antigen-independent and antigen- dependent assays were set up. In the first case, T cells were stimulated with anti-CD3/anti-CD28 beads and autologous DCs expressing tNGFR, sPD-1 or sPD-L1. In the second assay, T cells were stimulated with autologous DCs expressing influenza nuclear protein-1 (Flu NP1) and tNGFR, sPD-1 or sPD-L1. Interestingly, and in contrast to other published work with blocking antibodies or shRNA, [30] [31] [32] there were no significant differences in T-cell proliferation in our assays, unless we added a blocking anti-PD-L1 antibody to the cultures (Figures 4a and 5a , n ¼ 5).
In a second set of experiments, we assessed the expression of CD107a by CD8 þ T cells and secretion of multiple cytokines by CD4 þ and CD8 þ T cells. In the absence of a specific antigen, there were no differences in CD107a expression or cytokine secretion by CD4 þ or CD8 þ T cells that were stimulated with sPD-1 or sPD-L1 producing DCs (data not shown, n ¼ 5). In contrast, when CD8 þ T cells were stimulated with Flu NP1 expressing DCs that further produced sPD-1 or sPD-L1, we observed an increase in CD107a expression in comparison with T cells stimulated with DCs expressing Flu NP1 and tNGFR ( Figure 4b , n ¼ 5). Moreover, intracellular staining of the cytokines IL-2, IFN-g, TNF-a and MIP-1b in combination with CD107a staining demonstrated that the majority of CD8 þ T cells stimulated by Flu NP1 and tNGFR expressing DCs were characterized by the ability to display only a limited number of the evaluated markers, lacking T cells that simultaneously produce four to five of the evaluated markers (Figures 4c-e, n ¼ 5). Importantly, CD8
þ T cells stimulated with DCs in the presence of sPD-1 or sPD-L1 produced higher cytokine levels and displayed a multifunctional phenotype (Figure 4e) . Surprisingly, we did not observe an increase in multifunctional CD8 þ T cells when the blocking anti-PD-L1 antibody was added, during their stimulation by Flu NP1 and tNGFR expressing DCs (data not shown). Importantly, similar results were obtained for
Expression of sPD-1 or sPD-L1 by antigen presenting DCs in the immunological synapse does not induce Treg cells It is known that Treg cells and the PD-1/PD-L1 pathway are critically involved in tumor promotion and viral persistence. [33] [34] [35] [36] Moreover, it is known that PD-1 is expressed in and on Treg cells in these pathologies. 13, 14 Here, PD-1 is reported to have a role in the maintenance and function of Treg cells. 37, 38 However, whether or not the PD-1 pathway has a role in the expansion of Treg cells remains not yet clear.
First, we isolated Treg cells from peripheral blood cells of healthy donors using the MACS technology. These CD4 Subsequently, these cells were stained for Treg cell markers including CD127, CD25, Foxp3, CD27, CTLA-4 and PD-1. Treg cells were gated as CD127 À CD25 þ Foxp3 þ cells. These cells expressed high levels of CD27 but only expressed low to undetectable levels of CTLA-4 and PD-1 (Figure 6a , n ¼ 2).
As it is difficult to obtain large numbers of Treg cells from healthy donors and as these Treg cells did not show high expression of PD-1, we next evaluated whether DCs modified to present Flu NP1 and express tNGFR, sPD-1 or sPD-L1 were able to induce Treg cells upon stimulation of CD4 þ T cells. To that end, we followed the protocol as described by Pen et al. 40 We did not observe induction of Treg cells in any of the co-cultures (Figure 6b , n ¼ 2), although we previously described efficient expansion of Treg cells when CD4 þ T cells are stimulated with DCs electroporated with TriMix mRNA (a mix of immune modulating mRNA molecules) and MEK ED mRNA (a constitutive active form of MEK1 that activates the MAPK-ERK pathway). 40 To confirm the absence of Treg cell induction, we further determined the presence of TGF-b in the culture supernatants using a previously described indicator cell line. 41 No major differences in production of TGF-b were observed (Figure 6c , n ¼ 2). Of note, in line with our previous results, we observed enhanced stimulation of IFN-g producing cells in these co-cultures (data not shown, n ¼ 2), demonstrating that in this setting the engineered DCs only have an impact on effector T-cell stimulation. DISCUSSION PD-L1/PD-1 negative co-stimulation is a mechanism that controls the activation state of T cells during antigen presentation by DCs, through a variety of mechanisms. [30] [31] [32] 42 Thus, T cells activated in the absence of PD-L1/PD-1 co-stimulation are hyperactivated, exhibiting increased proliferation and higher levels of cytokine expression. However, most of these studies have been performed using either blocking antibodies or RNA interference with shRNAs or siRNAs.
In this study, we interrupted the PD-L1/PD-1 co-stimulation in the immunological synapse by expressing soluble forms of either the ligand or the receptor. The use of sPD-1 or PD-L1 may circumvent the necessity of administering blocking antibodies systemically, which bears the risk of toxicity. In addition, splice variants of both PD-L1 and PD-1 have been described. 43, 44 Although, the function of the PD-L1 splice variants (located at the inner cell membrane) is yet to be determined, it has been described that PD-1 splice variants give rise to sPD-1 that has been shown to be present in patients with rheumatoid arthritis as well as patients suffering from chronic lymphocytic leukemia. 45, 46 In rheumatoid arthritis, these PD-1 splice variants are thought to have a role in autoimmunity. 45 In chronic lymphocytic leukemia patients, these PD-1 splice variants were suggested to correlate with survival. 46 These findings further encourage us to evaluate sPD-1 and sPD-L1 as agents to enhance T-cell responses.
Our results show that interfering with this pathway using soluble ligands effectively improves the stimulatory capacity of DCs, which can be used to induce multifunctional CD4 þ and CD8 þ T cells from antigen-specific T cells. To our knowledge, most studies using blocking antibodies or RNA interference demonstrated that T cells hyper-proliferated and expressed higher levels of single cytokines such as IFN-g or IL-17 31 but did not show production of multiple cytokines.
The expression of sPD-1 has been used in past studies, leading to conflicting results. When sPD-1 was expressed from a DNA vector in a DC-based cancer vaccine in a mouse model, it enhanced DC maturation and T-cell responses. 47, 48 However, a second group found just the opposite, possibly due to differences in the experimental systems. 49 In this study, and to our knowledge, we are the first to use this strategy in a human system, in antigen-independent and antigen-dependent assays.
A key problem in cancer patients is cancer-induced immune suppression, hampering the DCs to achieve full phenotypic and functional maturation due to the presence of multiple immunosuppressive mechanisms. Therefore, DCs from cancer patients are not capable of efficiently stimulating T cells, partly because of the reduced surface expression of co-stimulatory molecules and the increased expression of IL-10. 50, 51 The same can be applied to ex vivo generated immature DCs, which do not attain full maturation probably because of the current culture/ differentiation conditions. By the targeted expression of sPD-1 or sPD-L1, the PD-L1 pathway can be inhibited in these DCs, which will lead to their partial maturation. This has been observed at least in mouse DCs. 47, 48 However, it is in chronic viral infections in which the PD-L1/PD-1 pathway has a critical immunosuppressive role, as it has been implicated in the gradual loss of T-cell function and cytokine secretion in human immunodeficiency virus and hepatitis B virus infections, a process called T-cell exhaustion. 52 The chronic stimulation of this pathway eliminates the multifunctionality of virus-specific T cells, leading to an inefficient viral clearance. In our study, we have used as a model a common viral antigen from influenza virus, the NP1. 53 Using this model system, we achieved stronger and multifunctional T-cell responses by expressing sPD-1 or sPD-L1 by the DCs. In contrast, antigen presentation in the absence of sPD-1 or sPD-L1 resulted in activation of antigenspecific T cells that only produced a single cytokine. This key difference could have several explanations, the simplest being the higher maturation status of the DCs. Curiously, in our study we did not observe an increase in T-cell proliferation, suggesting that expression of these soluble forms stimulates high-quality (cytokine producing) antigen-specific T cells.
In conclusion, blocking the PD-L1 pathway yields promising results in cancer and chronic viral infections, by stimulating DCs and indirectly T cells. The use of sPD-1 and sPD-L1 rather than antibodies adds a factor of safety against autoimmunity. In addition, our study suggests that different ways of interfering with this pathway may lead critically different qualitative results.
MATERIALS AND METHODS
Cell lines
Human embryonal kidney 293T cells (American Type Culture Collection) were cultured in Dulbecco's Modified Eagle Medium (Lonza, Verviers, Belgium), supplemented with 10% fetal bovine serum (Harlan, Horst, The Netherlands), 2 mM L-glutamine (Lonza), 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin (Lonza).
Lentivirus production, characterization and transduction of 293T cells
The packaging plasmid pCMVDR8.9 and the VSV.G encoding plasmid pMD.G were a kind gift from D Trono (University of Geneva). The cDNAs encoding human PD-1 or PD-L1 were obtained as PCR fragments starting from RNA obtained from activated T cells or DCs, respectively. These were cloned as SpeI-XhoI fragments in the pHR' trip CMV-Ires-tNGFR SIN, 54 resulting in pHR' trip CMV PD-1 SIN and pHR' trip CMV PD-L1 SIN. Enzymes were purchased from Fermentas (Vilnius, Lithuania). The production and characterization of lentiviral vectors was performed as described previously. 54, 55 In vitro transduction of 1 Â 10 5 293T cells was performed at a multiplicity of infection of 10, resulting in 293T cells that highly express PD-1 or PD-L1 (Supplementary Figure 1) .
Generation of human DCs
To generate human monocyte-derived DCs, the leukapheresis products of healthy donors were processed using the elutriation technique (Caridian). Fractions 2 and 3 were used as a source for T cells, while fraction 5 contains monocytes, which were used as DC precursors. Monocytes were cultured in complete DC medium, that is, Roswell Park Memorial Institute 1640 (RPMI-1640) medium (Cambrex, Charles City, IA, USA), supplemented with 1% autologous plasma, 20 mg ml À 1 gentamicin, 1000 U ml À 1 GM-CSF (prepared in-house) and 500 U ml À 1 IL-4 (prepared in-house). These cells were fed every 2 days with 1000 U ml À 1 GM-CSF and 500 U ml À 1 IL-4. On day 6, DCs were harvested and cryopreserved. 56 mRNA production
The vector, pST1 was provided by U Sahin (Johannes-Gutenberg University, Germany). The plasmid pGEM-eGFPbis and pST1-tNGFR was previously described. 57 The DNA sequence encoding the extracellular part of human PD-1 or PD-L1 was obtained as PCR fragments starting from cDNA obtained from activated T cells or DCs, respectively. These were cloned as HinDIII-XhoI fragments in the pST1 vector. During the PCR, we incorporated a myc tag in the PD-1 construct. The gene encoding the Flu NP1 was obtained as a BamHI fragment from the plasmid pFlu NP1-eGFP, which was a gift from A Osterhaus (Erasmus University Medical Center, Rotterdam). The Flu NP1 fragment was cloned into the pST1-sig DC-LAMP vector. 57 Enzymes were purchased from Fermentas. To produce mRNA, the pGEM and pST1 vectors were linearized with SapI and SpeI respectively before the in vitro mRNA synthesis. The protocol for in vitro transcription of mRNA and its subsequent quality control was previously described. 57 Electroporation of cells with mRNA Cells were electroporated using a previously described protocol. 58 Briefly, cells were washed twice in OptiMEM after which 4 Â 10 6 cells were resuspended in 200 ml OptiMEM containing 20 mg mRNA encoding tNGFR, sPD-1 or sPD-L1. Electroporation was performed using a voltage of 300 V, capacitance of 150 mF and resistance of 99 O resulting in a pulse time of 5-6 ms (GenePulser XCell; Bio-Rad, Nazareth Eke, Belgium). After the electroporation, the cells were immediately diluted in pre-warmed medium till further use.
Intracellular staining of sPD-1 and sPD-L1
To assess expression of sPD-1 and sPD-L1 after mRNA electroporation, modified 293T cells were cultured in the presence of 2 mg ml À 1 Brefeldin A for 16 h. Intracellular staining of the soluble molecules was performed using the BD Cytofix/Cytoperm kit and the following antibodies: an allophycocyanin (APC)-conjugated anti-PD-1 (MIH4; BD Biosciences, Erembodegem, Belgium) or anti-PD-L1 (MIH1; eBioscience) antibody. Non-modified 293T cells were used as controls. Samples were acquired using the FACSCanto flow cytometer (BD Biosciences), while fluorescence analysis was performed using the FlowJo (Tree Star Inc., Ashland, OR, USA) software.
Western blot
Twenty microliters of supernatants of lentivirally transduced 293T cells containing sPD-1 or sPD-L1 was separated on a 15% SDS-PAGE and transferred onto a nitrocellulose membrane. The following primary antibodies were used: biotinylated anti-PD-1 and anti-PD-L1 antibodies (R&D, Abingdon, UK). A streptavidin-conjugated horseradish peroxidase (Cell Signaling, Leiden, The Netherlands) was used for detection. Antibody binding was visualized using enhanced chemoluminescence (Pierce, Thermo Scientific, Waltham, MA, USA).
Enzyme-linked immunosorbent assay for detection of sPD-1 and sPD-L1
To determine the secretion of sPD-1 and sPD-L1 at 0-24, 24-48, 48-72 and 0-72 h after electroporation of 293T cells, supernatants were harvested at the indicated time points. In addition, supernatants that were collected 24 h after electroporation were stored at 37 1C to evaluate the stability of the soluble molecules. The presence of sPD-1 was evaluated using an anti-myc antibody (BioLegend, Imtec Daignostics, Antwerp, Belgium) and a biotin-conjugated anti-PD-1 antibody (clone J105; eBioscience), whereas sPD-L1 was evaluated using an anti-PD-L1 antibody (clone MIH5; eBioscience) and a biotin-conjugated anti-PD-L1 antibody (clone MIH1; eBioscience).
Binding assay
Binding of sPD-1 and sPD-L1 to their partners was determined by flow cytometry. PD-1 or PD-L1 expressing 293T cells were incubated with the soluble molecules for 1 h at 4 1C. Non-modified 293T cells served as a control. Binding of the soluble molecules was visualized using a biotinconjugated anti-PD-1 (clone J105; eBioscience) or anti-PD-L1 (clone MIH1l eBioscience) antibody, followed by detection using SA-APC (eBioscience). Samples were acquired using the FACSCanto flow cytometer, while fluorescence analysis was performed using the FlowJo software.
Maturation of DCs
Maturation of DCs was induced using IL-1b (100 U ml À 1 ), IL-6 (1000 U ml
), TNF-a (100 U ml
) and PGE 2 (1 mg ml À 1 ). 59 The cytokines TNF-a and PGE 2 were purchased from Peprotech Inc. (Rocky Hill, NJ, USA) and Sigma-Aldrich (Bornem, Belgium), respectively. The cytokines IL-1b and IL-6 were prepared in-house as previously described. 60 Treg cell stimulation After thawing of fractions 2 and 3 from the elutriation process, Treg cells were sorted by magnetic cell sorting. First, CD4
þ T cells were negatively selected using the CD4 þ T cell isolation kit II (Miltenyi Biotec, Bergisch Gladbach, Germany), after which this CD4 þ T cell-enriched population was stained with a phycoerythin (PE)-conjugated anti-CD25 antibody (Becton Dickinson, Erembodegem, Belgium), labeled with anti-PE beads (Miltenyi Biotec) and sorted by MACS. These cells were left unstimulated or were stimulated with rapamycin according to the protocol described by Strauss et al. 39 Briefly, Treg cells were cultured with allogeneic irradiated peripheral blood mononuclear cells, 50 IU ml À 1 IL-2 and 1 nM rapamycin. On days 7 and 14, Tregs were restimulated with allogeneic peripheral blood mononuclear cells, IL-2 and rapamycin. 
Cytokine secretion
The presence of IL-12, TNF-a (eBioscience) and IL-10 (R&D Systems) in supernatants from DC cultures was analyzed by ELISA.
T-cell proliferation assay
After thawing, bulk T cells (fractions 2 and 3 from the elutriation process) were sorted in CD4 þ and CD8 þ T cells by magnetic cell sorting (Miltenyi Biotec). These T cells were labeled with 0.3 mM carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes, Life Technologies, Paisley, UK).
CFSE-labeled T cells (10 5 cells per 100 ml) were cultured in round-bottom 96-well plates (Falcon, BD, Erembodegem, Belgium) in Iscove's Modified Dulbecco's Medium (IMDM; Gibco, Life Technologies), supplemented with 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin, 2 mM L-glutamine (Cambrex) and 1% human AB serum (referred to as complete T-cell medium). Modified DCs (with or without Flu NP1) were added at a DC-to-T cell ratio of 1:1 in 100 ml complete T-cell medium. In the absence of antigen, T cells were further stimulated with anti-CD3 beads, which were prepared using tosyl-activated dynabeads (Invitrogen, Life Technologies) and anti-CD3 antibody (clone OKT-3; prepared in-house). These were added at a beadto-T cell ratio of 1:1. After 6 days of co-culture, T cells were stained with NC605-conjugated anti-CD3, PerCP-Cy5.5-conjugated anti-CD4 and APC-Cy7-conjugated anti-CD8 antibodies (eBioscience). To assess proliferation of T cells (measured as dilution of CFSE), samples were acquired on the LSR-Fortessa flow cytometer and analyzed using the FlowJo software.
Multifunctionality assay
T cells were sorted as described supra, after which they were co-cultured with modified DCs (with or without Flu NP1). After 6 days of co-culture, Golgi Plug, Golgi Stop and CD107a Brilliant Violet (BioLegend) were added to the CD8 þ T-cell co-cultures. For CD4 þ T-cell co-cultures, only Golgi Plug was added. The following day, flow cytometry was performed to evaluate the exposure of CD107a. In addition, intracellular cytokine staining was performed to assess the production of TNF-a (FITC), IFN-g (PE), IL-2 (APC) and MIP-1b (PE-Cy7) (eBioscience). To evaluate induction of Treg cells by DCs modified to secrete sPD-1 or sPD-L1, stimulated CD4 þ T cells were stained for CD4, CD25, CD127 and Foxp3 as described supra.
TGF-b detection
The TGF-b indicator cell line, expressing eGFP under the control of SMAD, was previously described. 41 This indicator cell line was used to detect the presence of TGF-b in supernatants from cultures in which CD4 þ T cells were stimulated with DCs presenting Flu NP1 and expressing tNGFR, sPD-1 or sPD-L1.
Statistical analysis
Where appropriate, a paired Student's t-test, a two-way or one-way ANOVA was performed with post hoc Bonferroni correction. Differences were considered as significant at Po0.05. Statistical significance is indicated in the figures as * (Po0.05), ** (Po0.01) or *** (Po0.001).
